Back to top
more

KalVista Pharmaceuticals, Inc. (KALV)

(Delayed Data from NSDQ)

$18.43 USD

18.43
40,258

-0.83 (-4.31%)

Updated Dec 2, 2020 04:00 PM ET

After-Market: $18.41 -0.02 (-0.11%) 4:58 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (177 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y

Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line

Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4

Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA

The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.

The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx

The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx

5 Defensive Stocks to Counter Coronavirus Scare

Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.

BioLineRx Concludes Recruitment in Pancreatic Cancer Study

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

Will KalVista Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.

Kinjel Shah headshot

Prospects Appear Bright for Small Drug Industry in 2020

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.

Will KalVista Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in KalVista.

KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).

KalVista Sees Hammer Chart Pattern: Time to Buy?

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KalVista Pharmaceuticals Enters Oversold Territory

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

KalVista Group Sees Hammer Chart Pattern: Time to Buy?

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KalVista Pharmaceuticals Enters Oversold Territory

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Moving Average Crossover Alert: KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Rigel Initiates Enrollment in Pivotal Blood Disorder Study

Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.

KalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's Why

KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Kinjel Shah headshot

Small Drug Stocks Outlook: Near-Term Prospects Encouraging

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.

Kinjel Shah headshot

Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

What Makes KalVista Pharmaceuticals (KALV) a Strong Momentum Stock: Buy Now?

Does KalVista Pharmaceuticals (KALV) have what it takes to be a top stock pick for momentum investors? Let's find out.

Will KalVista Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.

Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings

Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.